Bright Minds Biosciences Statistics
Share Statistics
Bright Minds Biosciences has - shares outstanding. The number of shares has increased by 18.34% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.06M |
| Failed to Deliver (FTD) Shares | 21.42K |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 322.61K, so 4.64% of the outstanding shares have been sold short.
| Short Interest | 322.61K |
| Short % of Shares Out | 4.64% |
| Short % of Float | 6.38% |
| Short Ratio (days to cover) | 0.04 |
Valuation Ratios
The PE ratio is -1.08 and the forward PE ratio is null.
| PE Ratio | -1.08 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.21 |
| P/FCF Ratio | -1.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Bright Minds Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 24.26, with a Debt / Equity ratio of 0.
| Current Ratio | 24.26 |
| Quick Ratio | 24.26 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -373 |
Financial Efficiency
Return on equity (ROE) is -1.12% and return on capital (ROIC) is -108.14%.
| Return on Equity (ROE) | -1.12% |
| Return on Assets (ROA) | -1.07% |
| Return on Capital (ROIC) | -108.14% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 2646.67% in the last 52 weeks. The beta is 1.13, so Bright Minds Biosciences 's price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | 2646.67% |
| 50-Day Moving Average | 35.71 |
| 200-Day Moving Average | 9.81 |
| Relative Strength Index (RSI) | 51.13 |
| Average Volume (20 Days) | 3.06M |
Income Statement
In the last 12 months, Bright Minds Biosciences had revenue of $0 and earned -$7.37M in profits. Earnings per share was $-1.98.
| Revenue | 0 |
| Gross Profit | -72.45K |
| Operating Income | -7.21M |
| Net Income | -7.37M |
| EBITDA | -7.28M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.98 |
Balance Sheet
The company has $6.75M in cash and $73.55K in debt, giving a net cash position of $6.67M.
| Cash & Cash Equivalents | 6.75M |
| Total Debt | 73.55K |
| Net Cash | 6.67M |
| Retained Earnings | -31.55M |
| Total Assets | 6.28M |
| Working Capital | 6.09M |
Cash Flow
In the last 12 months, operating cash flow was -$7.02M and capital expenditures $5, giving a free cash flow of -$7.02M.
| Operating Cash Flow | -7.02M |
| Capital Expenditures | 5 |
| Free Cash Flow | -7.02M |
| FCF Per Share | -1.89 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.81% |
| FCF Yield | -2.45% |
Analyst Forecast
The average price target for DRUG is $75, which is 82% higher than the current price. The consensus rating is "Buy".
| Price Target | $75 |
| Price Target Difference | 82% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 14, 2023. It was a backward split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 913.73 |
| Piotroski F-Score | 2 |